Dr Andrew John McGlashan Richards
Dr Andrew John McGlashan Richards was appointed in a total of 23 companies and resigned from 20 of these appointments.
Role
Director
Country Of Residence
United Kingdom
Nationality
British
Date of Birth
March 1960
Occupations
Company Director • Biotechnology Entrepreneur • None • Consultant • Business Development Consultan • Executive Director
Active
2
Resigned
20
Dissolved
1
Other
0
Total
23
Companies
| Company | Timeline | Status | |
| Scale-Up Institute Director • Company Director | 19 Sep 2018←4 Years→30 Nov 2022 | Active | |
| Ieso Digital Health Limited Director • Biotechnology Entrepreneur | 12 May 2011←14 Years→Current | Active | |
| Abcodia Limited Director • None | 12 Jan 2011←11 Years→26 Sep 2022 | Active | |
| Ixico Technologies Limited Director • Director | 2 Sep 2009←4 Years→14 Oct 2013 | Active | |
Novacta Biosystems Limited Director • Director | 31 Jul 2009←9 Years→8 Apr 2019 | Dissolved | |
| Arecor Limited Director • Director | 11 Sep 2008←12 Years→21 Jun 2021 | Active | |
| Summit Therapeutics Limited Director • Consultant | 22 Mar 2007←5 Years→21 Nov 2012 | Active | |
| Altacor Limited Director • Director | 15 Dec 2006←7 Years→31 Jul 2014 | Active | |
| Aitua Limited Director • Director | 27 Jun 2006←3 Years→12 Nov 2009 | Dissolved | |
Pharmakodex Limited Director • Director | 12 May 2006←2 Years 9 Months→23 Feb 2009 | Dissolved | |
Mutual People
- Peter Stephen KeenVectura Group Limited, Paradigm Therapeutics Limited, Sosei R&D Ltd, and 1 more are mutual companies.
- Mr Glyn Owain EdwardsSummit Therapeutics Limited, Summit (Cambridge) Limited and Bioindustry Association are mutual companies
- Anne Philomena HylandVectura Group Limited and Pharmakodex Limited are mutual companies.
- Mr Darren Michael MillingtonSummit (Cambridge) Limited and Summit Therapeutics Limited are mutual companies.
Financials, Credit Activity, Owners, and more
Completely understand the businesses you work with
Make key decisions on clients and suppliers faster, discover leads and connect with decision makers, and easily monitor opportunities that get better through time
